NEW YORK (GenomeWeb News) – Atossa Genetics today said into has signed a nationwide agreement with preferred provider organization HealthSmart.
The agreement, the Seattle-based breast cancer diagnostic firm said, is to provide patients in HealthSmart's network greater access to Atossa's ForeCyte Breast Health Test. The risk stratification test for breast cancer is based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT.
Based in Irving, Texas, HealthSmart specializes in self-funded insurance solutions, according to Atossa.
Today's announcement is the third deal between Atossa, which went public in November, and a PPO. It also reached a payor agreement in March with FedMed, and in September, the company inked a deal with managed healthcare plan MultiPlan's networks.
Financial and other terms of the deal were not disclosed.